Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 7/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28431957 | 1.00 | KDM4E (0.53) | KDM4ERCE1MAPK1EGFRKDM1A | |
| Hydrochloric Acid SCHEMBL4378498 | 0.99 | KDM4E (0.52) | KDM4ERCE1MAPK1EGFRKDM1A | |
| SCHEMBL4373778 | 0.89 | EHMT2 (0.52) | KDM4EALDH1A1KDRKMT2A | |
| SCHEMBL4379746 | 0.87 | EHMT2 (0.43) | KDM4ERCE1EGFRALDH1A1KDR | |
| SCHEMBL29478513 | 0.83 | KDM1A (0.57) | KDM4EEGFRKDM1ASRCAURKA | |
| SCHEMBL29478512 | 0.83 | KDM1A (0.57) | KDM4EEGFRKDM1ASRCAURKA | |
| SCHEMBL1734721 | 0.83 | KDM1A (0.57) | KDM4EEGFRKDM1ASRCAURKA | |
| SCHEMBL829762 | 0.83 | KDM1A (0.57) | KDM4EEGFRKDM1ASRCAURKA | |
| SCHEMBL6433993 | 0.83 | SRC (0.56) | KDM4ERCE1MAPK1EGFRKDM1A | |
| Hydrochloric Acid SCHEMBL4378504 | 0.82 | KDM1A (0.56) | KDM4EEGFRKDM1ASRCAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8318932-B2 | Process for producing 4-aminoquinazoline compound | UBE INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-1481971-B1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES (JP) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011131610-A1 | HEAT TRANSFER MEDIUM BASED ON SULPHUR AND USE OF THE HEAT TRANSFER MEDIUM | SIEMENS AKTIENGESELLSCHAFT (DE) | 2011-10-27 | — | — | WO | disclosed |
| EP-1477481-B1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20090171083-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| US-20080177069-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20050130995-A1 | Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound | UBE INDUSTRIES, LTD. (JP) | 2005-06-16 | — | — | US | disclosed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1481971-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | Ube Industries, Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171083-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | HRH4, CYP3A4, HRH3 | KDM4E 639/4885RCE1 1180/4885MAPK1 1781/4885 |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | NQO2, SDHA, CYP3A4 | KDM4E 879/4885RCE1 752/4885MAPK1 1786/4885 |
| US-20080177069-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | HRH4, CYP3A4, HRH3 | KDM4E 639/4885RCE1 1180/4885MAPK1 1781/4885 |
| US-20050130995-A1 | Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound | HRH4, HRH3, H1-4 | KDM4E 2077/4885RCE1 1842/4885MAPK1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.